Date: 2016-01-14
Type of information: Resignation
Compound:
Company: Swedish Orphan Biovitrum - SOBI (Sweden)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease: Rare diseases
Details: * On January 14, 2016, Swedish Orphan Biovitrum (Sobi) announced that Birgitte Volck, M.D., Ph.D., Senior Vice President of Development and Chief Medical Officer (CMO) of Sobi, will leave the company to join the rare disease research group at GSK as Head of R&D Rare Diseases. Birgitte will work through a six month notice period before leaving Sobi.
Financial terms:
Latest news:
